| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8807223 | Annals of Diagnostic Pathology | 2018 | 28 Pages |
Abstract
PD-L1 expression is frequent in type B (B1/B2/B3) thymomas. It can be easily evaluated by IHC even on small biopsies in unresectable cases, thereby enabling improved clinical evaluation as well as prognostic stratification of patients. It will serve as a potential indicator for benefit from anti-PD-L1 antibody immunotherapy in thymomas.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Prerna Guleria, Nuzhat Husain, Saumya Shukla, Sunil Kumar, Rajinder Parshad, Deepali Jain,